CHICAGO -- November 14, 2008 -- Individuals with higher education levels appear to score higher on cognitive tests despite having evidence of brain plaques associated with Alzheimer's disease, according to a study in the November issue of Archives of Neurology.
"Adjusting for level of Alzheimer disease pathological burden determined at autopsy, greater education has been associated with better cognitive function during life," the authors wrote.
"Education interacts with Alzheimer disease pathological burden such that a greater pathological burden is required to show an effect on cognition among persons with more education."
Catherine M. Roe, PhD, Washington University School of Medicine, St. Louis, Missouri, and colleagues studied 37 individuals with dementia of the Alzheimer type and 161 individuals without dementia between 2003 and 2008.
Participants reported their education history and took cognitive tests. They were injected with carbon 11-labeled Pittsburgh Compound B ([11C]PiB) and then underwent a 60-minute positron emission tomography (PET) scan of the brain.
The level of [11C]PiB uptake interacted significantly with years of education in predicting cognitive test scores. Among individuals whose brains took up higher levels of [11C]PiB, indicating the presence of beta-amyloid plaques, performance on the test increased with increasing education levels. Education was not associated with cognitive scores among those with low [11C]PiB uptake, indicating no plaques.
"The results support the hypothesis that cognitive reserve influences the association between Alzheimer disease pathological burden and cognition. Based on autopsy data, there may be a ceiling effect when extensive beta-amyloid pathological burden is present as in late-stage dementia of the Alzheimer type," the authors wrote.
"Presumably, as the Alzheimer disease pathological burden increases, a greater proportion of highly educated participants reaches the threshold for dementia and the initial advantage provided by cognitive reserve decreases. Longitudinal imaging of beta-amyloid pathology in vivo will soon allow us to determine whether these inferences from cross-sectional studies are accurate."
SOURCE: Journal of the American Medical Association
E-Mail this DGNews to a colleague
